Patent ID: 11946939
Assignee: LABORATORY CORPORATION OF AMERICA HOLDINGS
Field: Measurement (Instruments)
Classification: CPC G | IPC G

Claim 0:
1. A method for treating cardiovascular disease (CVD) or infection in a subject with rheumatoid arthritis (RA), the method comprising:
performing an immunoassay on a sample from the subject to generate a dataset comprising protein level data for at least four protein markers of the group comprising chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1); C-reactive protein, pentraxin-related (CRP); epidermal growth factor (beta-urogastrone) (EGF); interleukin 6 (interferon, beta 2) (IL6); leptin (LEP); matrix metallopeptidase 1 (interstitial collagenase) (MMP1); matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3); resistin (RETN); serum amyloid A1 (SAA1); tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A); vascular cell adhesion molecule 1 (VCAM1); and, vascular endothelial growth factor A (VEGFA), wherein the at least four protein markers comprise LEP, CRP, CHI3L1, and MMP1; and
calculating a risk score for the sample indicating CVD or infection present in the subject by combining the dataset with a clinical parameter and a clinical assessment; and
administering a therapeutic regimen to the subject comprising one or more of:
administering a therapeutic compound selected from a Disease-modifying antirheumatic drug (DMARD), a biologic DMARD, a non-steroidal anti-inflammatory drug (NSAID), and a corticosteroid;
administering dietary modification and/or supplementation; and
administering bariatric surgical intervention.